ICON is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University (CMU), to find new ways to improve information comprehension and retention by clinical trial participants.
Acquisition extends ICON’s leadership in commercialisation and market access services and brings new scientific communications capabilities.
'Firecrest Through the Body' combines Firecrest’s clinical pharmacology and graphic design expertise to create a truly unique, animated view of systems inside the body.
ICON aims to address an unmet need for a well-defined, reliable endpoint that can measure the effects of antibacterial drugs on HABP patients.
Net new business awards of $468M, backlog grew to $3.5B, revenue up 14.1% YOY to $388M aand EPS was 79c.